Exact Sciences CorpNASDAQ:EXAS
- LAST PRICE66.8100
- TODAY'S CHANGE (%)0.8500 (1.2887%)
- Bid / Lots66.7100/ 4
- Ask / Lots66.8600/ 2
- Open / Previous Close65.8200 / 65.9600
- Day Range
- 52 Week Range
- Volume440,022
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EXAS |
|---|---|---|
| 09:32 ET | 15231 | 66.15 |
| 09:34 ET | 1700 | 66.31 |
| 09:36 ET | 509 | 66.27 |
| 09:38 ET | 3750 | 66.55 |
| 09:39 ET | 1316 | 66.74 |
| 09:41 ET | 3100 | 66.575 |
| 09:43 ET | 1750 | 66.62 |
| 09:45 ET | 403 | 66.675 |
| 09:48 ET | 5101 | 66.48 |
| 09:50 ET | 1068 | 66.535 |
| 09:52 ET | 1200 | 66.505 |
| 09:54 ET | 400 | 66.53 |
| 09:56 ET | 1999 | 66.29 |
| 09:57 ET | 61916 | 66.4 |
| 09:59 ET | 30140 | 66.54 |
| 10:01 ET | 5093 | 66.505 |
| 10:03 ET | 14001 | 66.415 |
| 10:06 ET | 1101 | 66.4 |
| 10:08 ET | 13183 | 66.38 |
| 10:10 ET | 2145 | 66.395 |
| 10:12 ET | 9900 | 66.34 |
| 10:14 ET | 2540 | 66.4 |
| 10:15 ET | 902 | 66.405 |
| 10:17 ET | 1016 | 66.442 |
| 10:19 ET | 9057 | 66.455 |
| 10:21 ET | 1653 | 66.25 |
| 10:24 ET | 1844 | 66.37 |
| 10:26 ET | 800 | 66.27 |
| 10:28 ET | 714 | 66.31 |
| 10:30 ET | 9227 | 66.41 |
| 10:32 ET | 1806 | 66.38 |
| 10:33 ET | 1021 | 66.305 |
| 10:35 ET | 3629 | 66.41 |
| 10:37 ET | 1809 | 66.42 |
| 10:39 ET | 3590 | 66.4 |
| 10:42 ET | 1600 | 66.47 |
| 10:44 ET | 1611 | 66.43 |
| 10:46 ET | 1978 | 66.435 |
| 10:48 ET | 1997 | 66.425 |
| 10:50 ET | 30364 | 66.5 |
| 10:51 ET | 2412 | 66.445 |
| 10:53 ET | 1300 | 66.43 |
| 10:55 ET | 4529 | 66.53 |
| 10:57 ET | 13523 | 66.565 |
| 11:00 ET | 359 | 66.56 |
| 11:02 ET | 4330 | 66.51 |
| 11:04 ET | 7564 | 66.505 |
| 11:06 ET | 3325 | 66.62 |
| 11:08 ET | 7851 | 66.54 |
| 11:09 ET | 1488 | 66.62 |
| 11:11 ET | 1065 | 66.62 |
| 11:13 ET | 2644 | 66.68 |
| 11:15 ET | 655 | 66.64 |
| 11:18 ET | 2590 | 66.705 |
| 11:20 ET | 1400 | 66.68 |
| 11:22 ET | 730 | 66.72 |
| 11:24 ET | 6845 | 66.69 |
| 11:26 ET | 11452 | 66.85 |
| 11:27 ET | 1262 | 66.795 |
| 11:29 ET | 2254 | 66.82 |
| 11:31 ET | 479 | 66.79 |
| 11:33 ET | 1300 | 66.8 |
| 11:36 ET | 2457 | 66.8 |
| 11:38 ET | 4371 | 66.71 |
| 11:40 ET | 3051 | 66.81 |
Sep 23, 2024
DJ S&P 500 Futures Up In Premarket Trading; Simpson Manufacturing, Intel Lead, from 7:30AM ET on Monday Sep 23, 2024 by Dow Jones
7:30AM ET on Monday Sep 23, 2024 by Dow Jones
Sep 17, 2024
DJ The Battle Brewing Over Blood Tests for Cancer -- Heard on the Street -- WSJ, from 7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ S&P 500 Futures Flat In Premarket Trading; Nuvalent, Bausch + Lomb Lead, from 7:30AM ET on Monday Sep 16, 2024 by Dow Jones
7:30AM ET on Monday Sep 16, 2024 by Dow JonesExact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024, from 2:35AM ET on Monday Sep 16, 2024 by Dow Jones
2:35AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
DJ Exact Sciences Is Maintained at Buy by Canaccord Genuity, from 2:45PM ET on Friday Sep 13, 2024 by Dow Jones
2:45PM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exact Sciences Corp | 12.1B | -69.5x | --- |
United Therapeutics Corp | 15.1B | 16.5x | +8.22% |
Neurocrine Biosciences Inc | 12.3B | 34.7x | +62.04% |
Biomarin Pharmaceutical Inc | 16.2B | 53.2x | --- |
Qiagen NV | 10.4B | 141.7x | +12.66% |
Medpace Holdings Inc | 10.9B | 31.1x | +35.10% |
Company Information
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Contact Information
- Headquarters
- 5505 Endeavor LaneMADISON, WI, United States 53719
- Phone
- 608-284-5700
- Fax
- 608-284-5701
Executives
- Chairman of the Board, President, Chief Executive Officer
- Kevin Conroy
- Chief Financial Officer
- Aaron Bloomer
- Executive Vice President, General Manager - Precision Oncology
- Brian Baranick
- Executive Vice President, General Manager - Screening
- Jacob Orville
- Executive Vice President - Human Resources
- Sarah Condella
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.1B |
|---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 184.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-0.96 |
Book Value | $17.34 |
P/E Ratio | -69.5x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 315.6x |
Operating Margin | -7.03% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
